Topical Wound Oxygen Therapy for Chronic Diabetic Ulcers
AOTI (LSE:AOTI), Inc. has accelerated the commercial expansion of its proprietary medical technology across international healthcare markets, addressing the critical clinical challenge of non-healing diabetic foot ulcers and chronic wounds. Admitted to trading on AIM in mid-2024 and an active constituent of the FTSE AIM All-Share index, the US-incorporated medical technology company designs and manufactures its patented Topical Wound Oxygen (TWO2) therapy systems. The TWO2 platform delivers cyclical pressurized topical oxygen directly to wounds in a home-care setting, stimulating tissue healing, reducing infection rates, and preventing lower-limb amputations.
Expanding Reimbursement Coverage Across US Healthcare Payors
The primary growth catalyst for AOTI is expanding commercial insurance and government reimbursement coverage across the United States healthcare ecosystem. The US Veterans Health Administration (VA) and Medicare have established dedicated reimbursement coding for TWO2 therapy, recognizing extensive clinical trial data demonstrating superior wound closure rates compared to standard wound care dressings. AOTI operates a direct clinical sales team that collaborates with wound care physicians and VA medical centres, providing turnkey patient home delivery and clinical monitoring services.
Clinical Evidence Generation and International Market Expansion
To drive global healthcare adoption, AOTI (LSE:AOTI) has invested heavily in peer-reviewed clinical studies and health economic evaluations. Published randomized controlled trials have confirmed that TWO2 therapy delivers sustained, long-term healing while significantly reducing overall hospitalisation rates and healthcare expenditures for chronic wound patients. Outside its dominant US market, the company is expanding commercial distribution across the United Kingdom NHS, Germany, and select Asia-Pacific territories through specialized medical device distributors.
Financial Performance, Revenue Growth, and Operating Cash Flow
In its published statutory accounts and interim financial disclosures, AOTI (LSE:AOTI) reported solid double-digit revenue growth driven by increasing patient treatment volumes and expanding commercial insurance authorizations. Gross profit margins remained high, reflecting the proprietary nature of its consumable oxygen treatment chambers. The company does not currently pay a dividend, reinvesting operational cash flows into expanding its clinical sales force, scaling Manufacturing capacity, and supporting ongoing clinical registry studies.
Healthcare Payer Dynamics and Forthcoming Strategic Milestones
AOTI (LSE:AOTI) operates in a US healthcare procurement environment where maintaining prompt claim processing and payer policy compliance is vital. Over the coming twelve months, key milestones include securing additional commercial payer coverage contracts across private US health plans, expanding European hospital pilot programmes, and reporting audited full-year financial accounts confirming continued top-line revenue acceleration and operating profit progression.
Sector Context and Market Backdrop
Chronic wounds, including diabetic foot ulcers, are a major cost to healthcare systems because they can take a long time to heal and often require repeated treatment. Topical oxygen therapy is designed to deliver oxygen directly to the wound bed to support healing. A device that patients can use at home reduces the need for frequent clinic visits, which is one reason that continuity of care from hospital to home is an important theme in wound management.
What to Watch Next
Reimbursement is central to how medical technologies are adopted in the United States, so coverage decisions by Medicare, the Veterans Health Administration and commercial insurers are important milestones. Other points to follow include publication of clinical studies, patient treatment volumes and the expansion of European hospital pilot programmes. Gross margin trends reflect the consumable nature of the therapy, and updates on revenue growth help to show how adoption is progressing across the markets it serves.





_11_16_2026_07_31_57_000112.jpg)
Please wait processing your request...